Gliatech (GLIA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Torben Noerup Nielsen who wrote (1307)	2/5/2000 1:08:00 PM
From: Vector1	Read Replies (1) of 2001

Torben, The other Adcons have not been approved and the company has had trouble getting insurance reimbursent. This issue is not going to go away. My point is that the drug pipeline together with the Adcons is a negative synergy. That is why GENZ spun off the surgical division. ADCOn is too small for a spinoff or a tracking stock. When you sell something you have to leave money on the table for they buyer or you will never make a deal. As a shareholder would I take $16 a share in cash or stock for the Adcon business and ride with the drug pipeline. You bet. V1

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next